New York is currently home to 4441 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
Recruiting
Patients will receive one of two conditioning regimens (BEAM or CBV) before receiving an autologous stem cell transplant (ASCT). If patients achieve either complete, partial, or stable response following ASCT, they will receive an IV dose of Polatuzumab Vedotin once every 21 days until they receive 8 doses. After Polatuzumab Vedotin therapy is completed, patients will be followed every 4 months for about 2 years.
Gender:
ALL
Ages:
Between 12 years and 70 years
Trial Updated:
10/24/2023
Locations: New York Medical Center, Valhalla, New York
Conditions: B-cell Lymphoma, Burkitt Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Transformed Non-Hodgkin Lymphoma, Richter Syndrome, Hodgkin Lymphoma
Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura
Recruiting
The purpose of this study is to determine if a dose dense administration of Rituximab in newly diagnosed acute immune thrombocytopenic purpura (ITP) and determine relapse rate following this treatment. Correlative studies will be performed as outlined in the appendices. Quality of Life will be measured using the KIT as outlined in the protocol.
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
10/24/2023
Locations: New York Medical College, Valhalla, New York
Conditions: Immune Thrombocytopenic Purpura
Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies
Recruiting
Investigators are testing new experimental drug combinations such as the combination of vorinostat, vincristine, irinotecan, and temozolomide in the hopes of finding a drug that may be effective against tumors that have come back or that have not responded to standard therapy. The goals of this study are: * To find the highest safe dose of vorinostat that can be given together with vincristine, irinotecan, and temozolomide without causing severe side effects; * To learn what kind of side effec... Read More
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
10/24/2023
Locations: New York Medical College, Valhalla, New York
Conditions: Ewing Sarcoma, Rhabdomyosarcoma, Wilms Tumor, Neuroblastoma, Hepatoblastoma, Germ Cell Tumor
AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
Recruiting
Children, adolescents, and young adults with malignant and non-malignant conditionsundergoing an allogeneic stem cell transplantation (AlloSCT) will have the stem cells selected utilizing α/β CD3+/CD19+ cell depletion. All other treatment is standard of care.
Gender:
ALL
Ages:
Between 1 day and 30 years
Trial Updated:
10/24/2023
Locations: New York Medical College, Valhalla, New York
Conditions: Acute Leukemia, Severe Aplastic Anemia, Non-hodgkin Lymphoma, Hodgkin Lymphoma, Kostmann, Diamond Blackfan Anemia, Amegakaryocytic Thrombocytopenia, Sickle Cell Disease, Beta-Thalassemia
Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma
Recruiting
Patients are in 2 cohorts: Cohort 1: dexamethasone, methotrexate, ifosfamide, pegaspargase, and etoposide (modified SMILE) chemotherapy regimen alone and pembrolizumab in children, adolescents, and young adults with advanced stage NK lymphoma and leukemia Cohort 2: combining pralatrexate (PRX) (Cycles 1, 2, 4, 6) and brentuximab vedotin (BV) (Cycles 3, 5) to cyclophosphamide, doxorubicin, and prednisone in children, adolescent, and young adults with advanced peripheral T-cell lymphoma (non-anap... Read More
Gender:
ALL
Ages:
Between 1 year and 31 years
Trial Updated:
10/24/2023
Locations: New York Medical College, Valhalla, New York
Conditions: NK-Cell Lymphoma, NK-Cell Leukemia, Peripheral T Cell Lymphoma
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
Recruiting
The purpose of this study is to determine the safety of administering obinutuzumab as a single agent alone and in combination with ifosfamide, carboplatin, and etoposide (ICE) chemotherapy and determine the response rate of this treatment for children, adolescents and young adults (CAYA) with relapsed CD20 positive B-cell Non-Hodgkin Lymphoma (B-NHL).
Gender:
ALL
Ages:
Between 3 years and 31 years
Trial Updated:
10/24/2023
Locations: New York Medical College, Valhalla, New York
Conditions: Non-Hodgkin Lymphoma, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, Primary Mediastinal B-cell Lymphoma, CD20+ Lymphoblastic Lymphoma, Follicular Lymphoma, Grade III
Triage Survey for Neurology Research Eligibility
Recruiting
TRIAGE-Neuro is a survey study designed to assess potential participants' eligibility to screen for industry-sponsored neurology clinical trials.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/23/2023
Locations: Berman Clinical, New York, New York
Conditions: Alzheimer Disease
APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma
Recruiting
This is a Phase Ib/II, open-label, multi-center study evaluating the safety, tolerability, efficacy, and PK/ Pharmacodynamics of APG-2575 in combination with Pd/DRd in patients with relapsed/refractory (RR) multiple myeloma (MM). The study consists of dose escalation and dose expansion phases. The study consists of will start with 2 arms noted below, both arms are independent
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/23/2023
Locations: Weil Cornell Medical Center, New York, New York
Conditions: Multiple Myeloma, Amyloidosis
TGNB CARE Mentalizing-Focused Parenting Groups (TGNB-CARE)
Recruiting
The primary objective of this pilot intervention study is to build upon the Connecting and Reflecting Experience (CARE) clinical trial \[Clinical Trials Number: NCT04580459\] and evaluate the acceptability, feasibility, and preliminary outcomes of CARE when implemented via tele-health among caregivers of transgender and nonbinary (TGNB) youth (TGNB-CARE). The main questions it aims to answer are: * To determine the feasibility and acceptability of the CARE treatment adaptation for caregivers o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/20/2023
Locations: Montefiore Medical Center, New York, New York
Conditions: Parent-Child Relations
Transcranial Ultrasound Via Sonolucent Cranioplasty
Recruiting
Transcranial Ultrasound via Sonolucent Cranioplasty is a prospective, single arm, observational, open label (non-blinded) study to collect real world evidence on the use of transcranial ultrasound via sonolucent cranioplasty.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/19/2023
Locations: Lenox Hill Hospital, New York, New York
Conditions: Cranioplasty, Sonolucent Cranioplasty, Reconstructive Cranioplasty
Triage Survey for Psychiatry Research Eligibility
Recruiting
TRIAGE-Psych is a survey study designed to assess potential participants' eligibility to screen for industry-sponsored psychiatry clinical trials.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/19/2023
Locations: Berman Clinical, New York, New York
Conditions: Major Depressive Disorder, Borderline Personality Disorder, Generalized Anxiety Disorder
CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition
Recruiting
The purpose of this study is to determine if the use of immunotherapy nivolumab and the targeted therapy cabozantinib prior to removal of the kidney, will increase the number subjects who are without any visible kidney cancer in their body at some point during the course of treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/19/2023
Locations: Columbia University Irving Medical Center, New York, New York
Conditions: Kidney Cancer, Renal Cell Carcinoma